Ben J. Marais

Prof. Dr. Ben J. Marais

Institute for Infectious Diseases and the Centre for Research Excellence in Tuberculosis, The University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
CPCarlos M. Perez-Velez
Carlos M. Perez-Velez
Ben J. MaraisBen J. Marais
Ben J. Marais
In areas where it is endemic, tuberculosis remains a major, often unrecognized cause of disease and death among children. Symptoms are often subtle, and sputum smears have limited utility. This review summarizes the principles of diagnosis, treatment, and prevention.

1 March 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
GMGiovanni Battista Migliori
Giovanni Battista Migliori
STSimon Tiberi
Simon Tiberi
AZAlimuddin Zumla
Alimuddin Zumla
EPEskild Petersen
Eskild Petersen
Chakaya Muhwa JeremiahChakaya Muhwa Jeremiah
Chakaya Muhwa Jeremiah
MNmembers of the Global Tuberculosis Network
members of the Global Tuberculosis Network
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.

21 January 2009
Verified
Reference Entry
Closed access
PDF file
LGLiesl Grobler
Liesl Grobler
Ben J. MaraisBen J. Marais
Ben J. Marais
SMSa Mabunda
Sa Mabunda
PMPn Marindi
Pn Marindi
HRHelmuth Reuter
Helmuth Reuter
JVJimmy Volmink
Jimmy Volmink

1 December 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
RKRichard Kock
Richard Kock
AMAnita Michel
Anita Michel
MYMichelle Korama Yeboah-Manu
Michelle Korama Yeboah-Manu
Esam AzharEsam Azhar
Esam Azhar
JTJordi B. Torrelles
Jordi B. Torrelles
AZAlimuddin Zumla
Alimuddin Zumla
Despite slow reductions in the annual burden of active human tuberculosis (TB) cases, zoonotic TB (zTB) remains a poorly monitored and an important unaddressed global problem. There is a higher incidence in some regions and countries, especially where close association exists between growing numbers of cattle (the major source of Mycobacterium bovis) and people, many suffering from poverty, and where dairy products are consumed unpasteurised. More attention needs to be focused on possible increased zTB incidence resulting from growth in dairy production globally and increased demand in low income countries in particular. Evidence of new zoonotic mycobacterial strains in South Asia and Africa (e.g. M. orygis), warrants urgent assessment of prevalence, potential drivers and risk in order to develop appropriate interventions. Control of M. bovis infection in cattle through detect and cull policies remain the mainstay of reducing zTB risk, whilst in certain circumstances animal vaccination is proving beneficial. New point of care diagnostics will help to detect animal infections and human cases. Given the high burden of human tuberculosis (caused by M. tuberculosis) in endemic areas, animals are affected by reverse zoonosis, including multi-drug resistant strains. This, may create drug resistant reservoirs of infection in animals. Like COVID-19, zTB is evolving in an ever-changing global landscape.

25 October 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
Mikaela ColemanMikaela Coleman
Mikaela Coleman
LMLeonardo Martinez
Leonardo Martinez
GTGrant Theron
Grant Theron
RWRobin Wood
Robin Wood
Ben J. MaraisBen J. Marais
Ben J. Marais
Tuberculosis has affected humankind for thousands of years, but a deeper understanding of its cause and transmission only arose after Robert Koch discovered Mycobacterium tuberculosis in 1882. Valuable insight has been gained since, but the accumulation of knowledge has been frustratingly slow and incomplete for a pathogen that remains the number one infectious disease killer on the planet. Contrast that to the rapid progress that has been made in our understanding SARS-CoV-2 (the cause of COVID-19) aerobiology and transmission. In this Review, we discuss important historical and contemporary insights into M. tuberculosis transmission. Historical insights describing the principles of aerosol transmission, as well as relevant pathogen, host and environment factors are described. Furthermore, novel insights into asymptomatic and subclinical tuberculosis, and the potential role this may play in population-level transmission is discussed. Progress towards understanding the full spectrum of M. tuberculosis transmission in high-burden settings has been hampered by sub-optimal diagnostic tools, limited basic science exploration and inadequate study designs. We propose that, as a tuberculosis field, we must learn from and capitalize on the novel insights and methods that have been developed to investigate SARS-CoV-2 transmission to limit ongoing tuberculosis transmission, which sustains the global pandemic.

14 May 2019 in Global Public Health
Verified
Journal Article
Closed access
Anna PalagyiAnna Palagyi
Anna Palagyi
Ben J. MaraisBen J. Marais
Ben J. Marais
SASeye Abimbola
Seye Abimbola
STStephanie M. Topp
Stephanie M. Topp
EMEmma McBryde
Emma McBryde
JNJoel Negin
Joel Negin
This review reflects on what the literature to date has taught us about how health systems of low- and middle-income countries (LMICs) respond to emerging infectious disease (EID) outbreaks. These findings are then applied to propose a conceptual framework characterising an EID prepared health system. A narrative synthesis approach was adopted to explore the key elements of LMIC health systems during an EID outbreak. Overarching themes (‘core health system constructs’) and sub-themes (‘elements’) relevant to EID preparedness were extracted from 49 peer-reviewed articles. The resulting conceptual framework recognised six core constructs: four focused on material resources and structures (i.e. system ‘hardware’), including (i) Surveillance, (ii) Infrastructure and medical supplies, (iii) Workforce, and (iv) Communication mechanisms; and two focused on human and institutional relationships, values and norms (i.e. system ‘software’), including (i) Governance, and (ii) Trust. The article reinforces the interconnectedness of the traditional health system building blocks to EID detection, prevention and response, and highlights the critical role of system ‘software’ (i.e. governance and trust) in enabling LMIC health systems to achieve and maintain EID preparedness. The review provides recommendations for refining a set of indicators for an ‘optimised’ health system EID preparedness tool to aid health system strengthening efforts.